July 21, 2016

The dust has settled from the ADA scientific sessions in New Orleans and we have had time to look at what we learned about SGLT-2 Inhibitors. There were at least 40 posters on how they work and what they can do, but there was not a whole lot about clinical use. The information from the recent AACE meeting had more of a clinical leaning. Our publisher, Steve Freed, had a chance to spend time with one of our Advisory Board members, Aaron Vinik, to get his clinical opinions on why some prescribers are sometimes hesitant to start a patient on an SGLT-2 inhibitor while others are ready to use them on all patients, including type 1s.

Dave Joffe
Editor-in-chief